Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2022 Annual Meeting | C75 - Neuro-oncology: Navigating Current Trends

Monday 04/04/22
01:00 PM - 03:00 PM PDT Add To Calendar
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Maciej M. Mrugala, MD, PhD, MPH, FAAN
Neuro-oncology
The learners will be able to acquire knowledge on the new WHO CNS tumors classification. New targeted therapies available to a neuro-oncologist will be discussed in detail. The faculty will cover both primary and metastatic brain tumors. Recent FDA-approved agents for the treatment of NF1 associated plexiform neurofibromas, as well as Von-Hipple Lindau disease-associated tumors, will be discussed.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist
Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM PDT Introduction Introduction
Maciej M. Mrugala, MD, PhD, MPH, FAAN
01:00 PM - 01:00 PM PDT Speaker walk in slides
Maciej M. Mrugala, MD, PhD, MPH, FAAN
01:05 PM - 01:40 PM PDT Speaker Contemporary Approach to Metastatic Disease in the CNS
Wendy Sherman, MD
01:40 PM - 02:20 PM PDT Speaker Deeper Dive into WHO CNS5 Classification with Practical Implications for a Neuro-oncologist
Craig Horbinski, MD
02:20 PM - 02:40 PM PDT Speaker Targeted Therapy in Neuro-oncology Clinic - Expanding Menu of Options
Maciej M. Mrugala, MD, PhD, MPH, FAAN
02:40 PM - 03:00 PM PDT Discussion Discussion & Questions and Answers
Maciej M. Mrugala, MD, PhD, MPH, FAAN, Craig Horbinski, MD, Wendy Sherman, MD
Faculty Disclosures
Maciej M. Mrugala, MD, PhD, MPH, FAAN Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Veevo Biomedicines Inc. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arbor Pharmaceuticals. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra-Zeneca. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyiatec . The institution of Dr. Mrugala has received research support from Arbor Pharmaceuticals. Dr. Mrugala has a non-compensated relationship as a Program Director with Society for Neuro-Oncology that is relevant to AAN interests or activities.
Wendy Sherman, MD Dr. Sherman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Focused ultrasound foundation . Dr. Sherman has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board Member with Kiyatec.
Craig Horbinski, MD Craig Horbinski, MD has nothing to disclose.